Use of serum amyloid protein P in preparation of related products for diagnosing and treating depression
A technology for serum amyloid and depression, applied in diagnosis, disease diagnosis, diagnostic recording/measurement, etc., can solve problems such as misdiagnosis of depression, lack of monoamine neurotransmitters, oxidative stress disorder, etc., and achieve high sensitivity and specificity Sexuality, convenient promotion and use, and easy access
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0064] Embodiment 1: the collection of peripheral blood and the method for measuring the concentration of peripheral blood SAP
[0065] 1. According to the approved ethical review experimental plan and diagnostic criteria, 91 cases of healthy controls and patients with depression (without medication or drug withdrawal for more than 6 weeks) were screened out, respectively, before treatment with the antidepressant escitalopram At 1 week and 12 weeks after treatment, the severity of depression was assessed by Hamilton Depression Rating Scale (HAMD), Rapid Depressive Symptom Scale (QIDS), Young Mania Scale (YMRS) and Depression Screening Scale (PHQ9). At the same time, 5 ml of peripheral blood was drawn into an EDTA anticoagulant tube, centrifuged at 3000 rpm for 10 minutes, and the upper layer of plasma was separated, and immediately aliquoted, stored in a -80°C ultra-low temperature refrigerator, and used for later use.
[0066] 2. On the Luminex 200 (Luminex, Austin, USA) plat...
Embodiment 2
[0078] Example 2: Peripheral blood SAP is used as a biomarker for the diagnosis of depression
[0079] 1. A total of 91 age- and gender-matched depression patients and 91 healthy controls were included in this study. The basic demographic information and patient symptom assessment of each group are shown in Table 2.
[0080] Table 2: Basic demographics of subjects and evaluation of clinical symptoms of patients
[0081]
[0082]
[0083] Note: HAMD: Hamilton Depression Rating Scale; QIDS: Rapid Depressive Symptom Rating Scale; YMRS: Young Mania Scale; PHQ9: Depression Screening Scale; NA: missing value.
[0084] After plasma SAP detection, it was found that compared with the healthy control group, the plasma SAP of patients with depression increased significantly ( Picture 1-1 , p=0.002), suggesting that plasma SAP concentration may be a potential biomarker for the diagnosis of depression. Combined with the subject's body mass index (BMI) and family history indicators, t...
Embodiment 3
[0085] Example 3: Peripheral blood SAP is used as a biomarker for predicting the efficacy of antidepressants
[0086] The depressive patients enrolled in the group were given the antidepressant escitalopram for treatment, and the depressive symptom scale was evaluated at 2 weeks, 4 weeks, 8 weeks and 12 weeks after treatment ( Figure 2-1 to Figure 2-4 ). After 12 weeks of antidepressant treatment, all the scores of the patients were significantly reduced, and the symptoms improved. However, some patients did not improve their symptoms significantly. After 12 weeks, the patients were divided into a treatment effective (Responders) group and a treatment ineffective (Non-responders) group according to the treatment effect (the reduction rate of the Hamilton Depression Scale reached 50%). Among them, there were 65 patients with effective treatment and 26 patients with ineffective treatment. from Figure 2-1 to Figure 2-4 It can be seen that although antidepressants have a cert...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com